Jill Fiedler‑Kelly Buys Low, Sells High as Simulations Plus Heads Toward $375 Million Altaris Deal.

Insider Activity Highlights a Strategic Shift

The latest director‑dealing filing shows President Jill Fiedler‑Kelly purchasing 7,350 shares of Simulations Plus on June 16, 2026 at $10.05, followed almost immediately by a Rule 10b5‑1 sale of the same number of shares at $18.20 and the exercise of 7,350 employee‑stock options. The transaction occurs just days after the company announced a definitive all‑cash acquisition by Altaris, valuing the business at roughly $375 million and offering a ~26 % premium to the 60‑day VWAP. The timing suggests that Fiedler‑Kelly’s activity is aligned with the impending deal—her buy at a lower price likely reflects a long‑term expectation of value, while the sale at the higher price coincides with the acquisition’s premium, maximizing proceeds for personal holdings.

Implications for Investors

For shareholders, the insider buying and selling pattern signals confidence in the company’s valuation trajectory. Fiedler‑Kelly’s purchases at $10.05 and $9.71—well below the current market price of $18.24—indicate a belief that the shares will continue to rally, especially given the merger’s projected cash payoff. Conversely, the rapid sale at $18.20 reflects an opportunistic exit that aligns with the acquisition’s premium, underscoring a short‑term liquidity strategy. Investors should view this as a mixed message: on the one hand, insider conviction; on the other, a tactical trade to capture the deal’s upside. The broader insider activity shows a cluster of high‑profile sales (e.g., Woltosz, DiBella, Evans) in June, which could be interpreted as a normal pre‑merger sell‑off or a sign of management hedging against post‑merger uncertainty.

Fiedler‑Kelly’s Insider Profile

Analyzing her historic transactions reveals a disciplined approach. Since January 28, 2026, she has alternated between buying and selling in roughly 1,000‑share increments at prices ranging from $9.71 to $16.53, often exercising options at no cost when fully vested. Her most recent pattern—buying at $10.05 and selling at $18.20—mirrors a classic “buy low, sell high” strategy, with option exercises indicating a willingness to lock in upside while mitigating dilution. The volume of her trades (about 7–8 k shares per move) is modest relative to her ownership stake, suggesting that she maintains a long‑term position while exploiting short‑term price differentials.

What This Means for the Company’s Future

The merger with Altaris will transform Simulations Plus from a public market entity to a private subsidiary, removing the need for ongoing public disclosures and potentially accelerating product integration with Chemical Computing Group. The premium paid reflects confidence in Synergy and a belief that the combined entity will command higher valuation multiples. Insider activity that aligns with the deal signals management’s endorsement of the transaction’s value proposition. For investors, this represents a transition point: either realize gains through the acquisition premium or hold the shares (if they become part of a private share structure) to benefit from the post‑merger upside. The overall trend of insider buying, coupled with the recent high‑profile sales, suggests that while executives are hedging against market volatility, they remain optimistic about long‑term returns under the new ownership structure.

Bottom Line

Jill Fiedler‑Kelly’s recent trades—buying at a low price and selling at a premium—underscore a bullish stance on Simulations Plus in the context of the Altaris acquisition. Her pattern of disciplined buying and opportunistic selling, combined with a modest option exercise strategy, points to a long‑term commitment tempered by short‑term liquidity optimization. For investors, the insider activity signals confidence in the merger’s value creation, but also highlights the impending shift from public to private ownership. The key takeaway is that the deal offers a significant premium now, with potential upside remaining tied to the success of the post‑merger integration and the broader health‑tech landscape.